IL17A and neoplasm: Collectively, these data suggest that IL-17 blockade could reduce the tumor burden in vivo. To verify this hypothesis, WT mice treated with DEN+CCl4 were intraperitoneally injected twice a week with 100 μg of anti-IL-17 neutralizing antibody or control isotype and for 6 weeks (Figure 7E).